{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:54:03Z","timestamp":1790394843949,"version":"4.1.0"},"reference-count":272,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T00:00:00Z","timestamp":1605139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004923","name":"AFM-T\u00e9l\u00e9thon","doi-asserted-by":"publisher","award":["22346"],"award-info":[{"award-number":["22346"]}],"id":[{"id":"10.13039\/501100004923","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2020.592234","type":"journal-article","created":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T05:48:05Z","timestamp":1605160085000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":36,"title":["Drug Screening and Drug Repositioning as Promising Therapeutic Approaches for Spinal Muscular Atrophy Treatment"],"prefix":"10.3389","volume":"11","author":[{"given":"Giovanna","family":"Menduti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela Maria","family":"Ras\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Stanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Boido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,11,12]]},"reference":[{"key":"B1","volume-title":"Ampyra highlights of prescribing information","year":"2017"},{"key":"B2","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.omtm.2018.01.007","article-title":"Plastin 3 promotes motor neuron axonal growth and extends survival in a mouse model of spinal muscular atrophy","volume":"9","author":"Alrafiah","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B3","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2147\/PGPM.S205082","article-title":"On the role of artificial intelligence in genomics to enhance precision medicine","volume":"13","author":"Azzouz","year":"2020","journal-title":"Pharm. Pers. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/ppul.24203","article-title":"Health outcomes in spinal muscular atrophy type 1 following AVXS\u2010101 gene replacement therapy","volume":"54","author":"Al\u2010Zaidy","year":"2018","journal-title":"Pediatr. Pulmonol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.pediatrneurol.2019.06.007","article-title":"From clinical trials to clinical practice: practical considerations for gene replacement therapy in SMA type 1","volume":"100","author":"Al-Zaidy","year":"2019","journal-title":"Pediatr. Neurol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1007\/s11064-019-02814-4","article-title":"The protective effects of levetiracetam on a human iPSCs-derived spinal muscular atrophy model","volume":"44","author":"Ando","year":"2019","journal-title":"Neurochem. Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.ejphar.2017.08.005","article-title":"Edaravone is a candidate agent for spinal muscular atrophy: in vitro analysis using a human induced pluripotent stem cells-derived disease model","volume":"814","author":"Ando","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/sj.ejhg.5201102","article-title":"Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy","volume":"12","author":"Andreassi","year":"2004","journal-title":"Eur. J. Hum. Genet."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1093\/hmg\/10.24.2841","article-title":"Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients","volume":"10","author":"Andreassi","year":"2001","journal-title":"Hum. Mol. Genet."},{"key":"B10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/jmg.2007.051177","article-title":"Salbutamol increases SMN mRNA and protein levels in spinal muscular atrophy cells","volume":"45","author":"Angelozzi","year":"2008","journal-title":"J. Med. Genet."},{"key":"B11","doi-asserted-by":"publisher","first-page":"102170","DOI":"10.1016\/j.ceca.2020.102170","article-title":"New perspectives for selective NCX activators in neurodegenerative diseases","volume":"87","author":"Annunziato","year":"2020","journal-title":"Cell Calcium"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jneumeth.2018.04.003","article-title":"Modelling motor neuron disease in fruit flies: lessons from spinal muscular atrophy","volume":"310","author":"Aquilina","year":"2018","journal-title":"J. Neurosci. Methods"},{"key":"B13","doi-asserted-by":"publisher","first-page":"5019","DOI":"10.1007\/s12035-017-0710-4","article-title":"Regulation of survival motor neuron protein by the nuclear factor-kappa B pathway in mouse spinal cord motoneurons","volume":"55","author":"Arumugam","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"B15","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1172\/JCI29562","article-title":"Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy","volume":"117","author":"Avila","year":"2007","journal-title":"J. Clin. Invest."},{"key":"B16","doi-asserted-by":"publisher","first-page":"153089","DOI":"10.1016\/j.phymed.2019.153089","article-title":"Improvement of spinal muscular atrophy via correction of the SMN2 splicing defect by Brucea javanica (L.) Merr. extract and Bruceine D","volume":"65","author":"Baek","year":"2019","journal-title":"Phytomedicine"},{"key":"B17","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1001\/archneur.62.1.128","article-title":"Intermittent Prednisone Therapy in Duchenne Muscular Dystrophy","volume":"62","author":"Beenakker","year":"2005","journal-title":"Arch. Neurol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"8466","DOI":"10.1523\/jneurosci.22-19-08466.2002","article-title":"Constitutive nuclear factor-\u03baB activity is required for central neuron survival","volume":"22","author":"Bhakar","year":"2002","journal-title":"J. Neurosci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/S0304-3940(02)00667-5","article-title":"Acetyl-l-carnitine shows neuroprotective and neurotrophic activity in primary culture of rat embryo motoneurons","volume":"329","author":"Bigini","year":"2002","journal-title":"Neurosci. Lett."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e0198116-14","DOI":"10.1371\/journal.pone.0198116","article-title":"A pharmaco-metabolomics approach in a clinical trial of ALS: identification of predictive markers of progression","volume":"13","author":"Blasco","year":"2018","journal-title":"PLoS One"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fncel.2018.00017","article-title":"Increasing agrin function antagonizes muscle atrophy and motor impairment in spinal muscular atrophy","volume":"12","author":"Boido","year":"2018","journal-title":"Front. Cell. Neurosci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3389\/fnana.2016.00006","article-title":"Neuromuscular junctions as key contributors and therapeutic targets in spinal muscular atrophy","volume":"10","author":"Boido","year":"2016","journal-title":"Front. Neuroanat."},{"key":"B23","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3390\/ph3020345","article-title":"Olesoxime (TRO19622): a novel mitochondrial-targeted neuroprotective compound","volume":"3","author":"Bordet","year":"2010","journal-title":"Pharmaceuticals"},{"key":"B24","doi-asserted-by":"publisher","first-page":"205031211881901","DOI":"10.1177\/2050312118819013","article-title":"Amifampridine phosphate in the treatment of muscle-specific kinase myasthenia gravis: a phase IIb, randomized, double-blind, placebo-controlled, double crossover study","volume":"6","author":"Bonanno","year":"2018","journal-title":"SAGE Open Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.1093\/hmg\/ddp310","article-title":"Zebrafish survval motor neuron mutants exhibit presynaptic neuromuscular junction defects","volume":"18","author":"Boon","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"B26","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1124\/jpet.107.123000","article-title":"Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis","volume":"322","author":"Bordet","year":"2007","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"B27","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/bpa.12071","article-title":"Spinal muscular atrophy: new findings for an old pathology","volume":"23","author":"Bottai","year":"2013","journal-title":"Brain Pathol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1093\/hmg\/ddr067","article-title":"Increased IGF-1 in muscle modulates the phenotype of severe SMA mice","volume":"20","author":"Bosch-Marc\u00e9","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnins.2014.00271","article-title":"ROCK inhibition as a therapy for spinal muscular atrophy\u202f: understanding the repercussions on multiple cellular targets","volume":"8","author":"Bowerman","year":"2014","journal-title":"Front. Neurosci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1093\/hmg\/ddq021","article-title":"Rho-kinase inactivation prolongs survival of an intermediate SMA mouse model","volume":"19","author":"Bowerman","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"B31","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1242\/dmm.030148","article-title":"Therapeutic strategies for spinal muscular atrophy\u202f: SMN and beyond","volume":"10","author":"Bowerman","year":"2017","journal-title":"Dis. Model Mech."},{"key":"B32","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1741-7015-10-24","article-title":"Fasudil improves survival and promotes skeletal muscle development in a mouse model of spinal muscular atrophy","volume":"10","author":"Bowerman","year":"2012","journal-title":"BMC Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.ejmg.2017.12.001","article-title":"Pathogenic commonalities between spinal muscular atrophy and amyotrophic lateral sclerosis: converging roads to therapeutic development","volume":"61","author":"Bowerman","year":"2018","journal-title":"Eur. J. Med. Genet."},{"key":"B34","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s12031-007-0024-5","article-title":"Smn depletion alters profilin II expression and leads to upregulation of the RhoA\/ROCK pathway and defects in neuronal integrity","volume":"32","author":"Bowerman","year":"2007","journal-title":"J. Mol. Neurosci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/hmg\/ddn320","article-title":"Deletion of smn-1, the Caenorhabditis elegans ortholog of the spinal muscular atrophy gene, results in locomotor dysfunction and reduced lifespan","volume":"18","author":"Briese","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"B36","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0733-8619(18)30939-3","article-title":"Intravenous thyrotropin-releasing hormone in patients with amyotrophic lateral sclerosis: dose-response and randomized concurrent placebo-controlled pilot studies","volume":"5","author":"Brooks","year":"1987","journal-title":"Neurol. Clin."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2202-10-84","article-title":"Fast, automated measurement of nematode swimming (thrashing) without morphometry","volume":"10","author":"Buckingham","year":"2009","journal-title":"BMC Neurosci."},{"key":"B38","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1126\/science.282.5396.2012","article-title":"Genome sequence of the nematode C. elegans: a platform for investigating biology [published correction appears in","volume":"283","year":"1998","journal-title":"Science"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e35037","DOI":"10.1371\/journal.pone.0035037","article-title":"Laterally Orienting C. elegans using geometry at microscale for high-throughput visual screens in neurodegeneration and neuronal development studies","volume":"7","author":"C\u00e1ceres","year":"2012","journal-title":"PLoS One"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1242\/dmm.028159","article-title":"Drug screening using model systems: some basics","volume":"9","author":"Cagan","year":"2016","journal-title":"Dis. Model. Mech."},{"key":"B41","doi-asserted-by":"publisher","first-page":"10067","DOI":"10.1021\/acs.jmedchem.6b00670","article-title":"Small molecules in development for the treatment of spinal muscular atrophy","volume":"59","author":"Calder","year":"2016","journal-title":"J. Med. Chem."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1200\/JCO.2004.08.141","article-title":"Gabapentin for neuropathic cancer pain: a randomized controlled trial from the gabapentin cancer pain study group","volume":"22","author":"Caraceni","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1159\/000097303","article-title":"The fly as a model for neurodegenerative diseases: is it worth the jump?","volume":"3","author":"Cauchi","year":"2007","journal-title":"Neurodegener. Dis."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/hmg\/ddg157","article-title":"Neuromuscular defects in a Drosophila survival motor neuron gene mutant","volume":"12","author":"Chan","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"B45","doi-asserted-by":"publisher","first-page":"e3209","DOI":"10.1371\/journal.pone.0003209","article-title":"Modeling spinal muscular atrophy in Drosophila","volume":"3","author":"Chang","year":"2008","journal-title":"PLoS One"},{"key":"B46","doi-asserted-by":"publisher","first-page":"9808","DOI":"10.1073\/pnas.171105098","article-title":"Treatment of spinal muscular atrophy by sodium butyrate","volume":"98","author":"Chang","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B47","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.1007\/s00018-018-2849-1","article-title":"The role of survival motor neuron protein (SMN) in protein homeostasis","volume":"75","author":"Chaytow","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/emmm.201202305","article-title":"Enhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug\u2010like compounds","volume":"5","author":"Cherry","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"11021","DOI":"10.1021\/acs.jmedchem.8b01291","article-title":"Discovery of small molecule splicing modulators of survival motor neuron-2 (SMN2) for the treatment of spinal muscular atrophy (SM)","volume":"61","author":"Cheung","year":"2018","journal-title":"J. Med. Chem."},{"key":"B50","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","article-title":"Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy","volume":"86","author":"Chiriboga","year":"2016","journal-title":"Neurology"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnbeh.2019.00141","article-title":"Gaboxadol normalizes behavioral abnormalities in a mouse model of fragile x syndrome","volume":"13","author":"Cogram","year":"2019","journal-title":"Front. Behav. Neurosci."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S1474-4422(14)70222-4","article-title":"Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial","volume":"13","author":"Cudkowicz","year":"2014","journal-title":"Lancet Neurol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.mcn.2014.06.006","article-title":"Autophagy dysregulation in cell culture and animals models of spinal muscular atrophy","volume":"61","author":"Custer","year":"2014","journal-title":"Mol. Cell. Neurosci."},{"key":"B54","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1750-1172-6-71","article-title":"Spinal muscular atrophy","volume":"6","author":"D\u2019Amico","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"B55","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/s12325-008-0030-1","article-title":"A preliminary report on spinal muscular atrophy lymphoblastoid cell lines: are they an appropriate tool for drug screening?","volume":"25","author":"Dayanga\u00e7-Erden","year":"2008","journal-title":"Adv. Ther."},{"key":"B56","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1039\/C8IB00091C","article-title":"Automated screening of C. elegans neurodegeneration mutants enabled by microfluidics and image analysis algorithms","volume":"10","author":"de Carlos C\u00e1ceres","year":"2018","journal-title":"Integr. Biol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41419-020-2688-5","article-title":"Calpain system is altered in survival motor neuron-reduced cells from in vitro and in vivo spinal muscular atrophy models","volume":"11","author":"de la Fuente","year":"2020","journal-title":"Cell Death Dis."},{"key":"B58","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1007\/s12035-018-1379-z","article-title":"Calpain inhibition increases SMN protein in spinal cord motoneurons and ameliorates the spinal muscular atrophy phenotype in mice","volume":"56","author":"de la Fuente","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.nbd.2010.05.012","article-title":"Neurodegenerative disorders: insights from the nematode Caenorhabditis elegans","volume":"40","author":"Dimitriadi","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"B60","doi-asserted-by":"publisher","first-page":"6557","DOI":"10.1523\/JNEUROSCI.1536-12.2013","article-title":"The neuroprotective drug riluzole acts via small conductance Ca2+-activated K+ channels to ameliorate defects in spinal muscular atrophy models","volume":"33","author":"Dimitriadi","year":"2013","journal-title":"J. Neurosci."},{"key":"B61","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.bbadis.2014.07.024","article-title":"Molecular mechanisms and animal models of spinal muscular atrophy","volume":"1852","author":"Edens","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"B62","doi-asserted-by":"publisher","first-page":"ddw278","DOI":"10.1093\/hmg\/ddw278","article-title":"Effect of genetic background on the phenotype of theSmn2B\/-mouse model of spinal muscular atrophy","volume":"25","author":"Eshraghi","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"B63","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/hmg\/ddt191","article-title":"Celecoxib increases SMN and survival in a severe spinal muscular atrophy mouse model via p38 pathway activation","volume":"22","author":"Farooq","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"B64","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1093\/hmg\/ddv629","article-title":"Pharmacologically induced mouse model of adult spinal muscular atrophy to evaluate effectiveness of therapeutics after disease onset","volume":"25","author":"Feng","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1038\/sj.bjp.0701320","article-title":"Gabapentin (neurontin) and S -(+)-3-isobutylgaba represent a novel class of selective antihyperalgesic agents","volume":"121","author":"Field","year":"1997","journal-title":"Br. J. Pharmacol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"eaaq1818-16","DOI":"10.1126\/scitranslmed.aaq1818","article-title":"Mouse models of neurodegeneration: know your question, know your mouse","volume":"11","author":"Fisher","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"B67","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.nbd.2016.01.008","article-title":"CNS uptake of bortezomib is enhanced by P-glycoprotein inhibition: implications for spinal muscular atrophy","volume":"88","author":"Foran","year":"2016","journal-title":"Neurobiol. Dis."},{"key":"B68","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1177\/1087057106292473","article-title":"High-throughput screening: update on practices and success","volume":"11","author":"Fox","year":"2006","journal-title":"J. Biomol. Screen"},{"key":"B69","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1210\/edrv-8-4-453","article-title":"Kinetics and dynamics of prednisolone*","volume":"8","author":"Frey","year":"1987","journal-title":"Endocr. Rev."},{"key":"B70","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.nmd.2019.04.003","article-title":"Salbutamol tolerability and efficacy in patients with spinal muscular atrophy type II","volume":"29","author":"Frongia","year":"2019","journal-title":"Neuromuscul. Disord."},{"key":"B71","doi-asserted-by":"publisher","first-page":"e15769","DOI":"10.1371\/journal.pone.0015769","article-title":"Molecular determinants of survival motor neuron (SMN) protein cleavage by the calcium-activated protease, calpain","volume":"5","author":"Fuentes","year":"2010","journal-title":"PLoS One"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF01059447","article-title":"Pharmacokinetics and bioavailability of prednisone and prednisolone in healthy volunteers and patients: a review","volume":"8","author":"Gambertoglio","year":"1980","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"B73","doi-asserted-by":"publisher","first-page":"3645","DOI":"10.1093\/hmg\/ddp313","article-title":"LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate","volume":"18","author":"Garbes","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"B74","doi-asserted-by":"publisher","first-page":"e686","DOI":"10.1038\/cddis.2013.209","article-title":"Survival motor neuron protein reduction deregulates autophagy in spinal cord motoneurons in vitro","volume":"4","author":"Garcera","year":"2013","journal-title":"Cell Death Dis."},{"key":"B75","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.nbd.2011.02.003","article-title":"A new model to study spinal muscular atrophy: neurite degeneration and cell death is counteracted by BCL-XL Overexpression in motoneurons","volume":"42","author":"Garcera","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"B76","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/S1470-2045(16)00009-7","article-title":"Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial","volume":"17","author":"Garcia-Manero","year":"2016","journal-title":"Lancet Oncol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/dmcn.14027","article-title":"Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps","volume":"61","author":"Gaidano","year":"2019","journal-title":"Dev. Med. Child Neurol."},{"key":"B78","unstructured":"FDA approves Genentech\u2019s Evrysdi (risdiplam) for treatment of spinal muscular atrophy (SMA) in adults and children 2 months and older2020"},{"key":"B79","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1002\/mus.25102","article-title":"Perceived efficacy of salbutamol by persons with spinal muscular atrophy: a mixed methods study","volume":"54","author":"Giovannetti","year":"2016","journal-title":"Muscle Nerve"},{"key":"B80","doi-asserted-by":"publisher","first-page":"4084","DOI":"10.1093\/hmg\/ddt258","article-title":"The DcpS inhibitor RG3039 improves survival, function and motor unit pathologies in two SMA mouse models","volume":"22","author":"Gogliotti","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"B81","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.1523\/JNEUROSCI.5775-11.2012","article-title":"Motor Neuron Rescue in Spinal Muscular Atrophy Mice Demonstrates That Sensory-Motor Defects Are a Consequence, Not a Cause, of Motor Neuron Dysfunction","volume":"32","author":"Gogliotti","year":"2012","journal-title":"J. Neurosci."},{"key":"B82","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1002\/bies.201100082","article-title":"Invertebrate models of spinal muscular atrophy: insights into mechanisms and potential therapeutics","volume":"33","author":"Grice","year":"2011","journal-title":"Bioessays"},{"key":"B83","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/ana.20548","article-title":"Hydroxyurea enhances SMN2 gene expression in spinal muscular atrophy cells","volume":"58","author":"Grzeschik","year":"2005","journal-title":"Ann. Neurol."},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2019.00156","article-title":"Dissecting the extracellular complexity of neuromuscular junction organizers","volume":"6","author":"Guarino","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"B85","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1002\/mus.10455","article-title":"Riluzole attenuates spinal muscular atrophy disease progression in a mouse model","volume":"28","author":"Haddad","year":"2003","journal-title":"Muscle Nerve"},{"key":"B86","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/j.1471-4159.2006.03868.x","article-title":"In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy","volume":"98","author":"Hahnen","year":"2006","journal-title":"J. Neurochem."},{"key":"B87","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1177\/2472555220922802","article-title":"Target-directed approaches for screening small molecules against RNA targets","volume":"25","author":"Haniff","year":"2020","journal-title":"SLAS Discov."},{"key":"B88","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1750-1326-6-24","article-title":"Generation and Characterization of a genetic zebrafish model of SMA carrying the human SMN2 gene","volume":"6","author":"Hao","year":"2011","journal-title":"Mol. Neurodegener."},{"key":"B89","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.nbd.2017.09.005","article-title":"ERK and ROCK functionally interact in a signaling network that is compensationally upregulated in spinal muscular atrophy","volume":"108","author":"Hensel","year":"2017","journal-title":"Neurobiol. Dis."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fneur.2020.00045","article-title":"The need for SMN-independent treatments of spinal muscular atrophy (SMA) to complement SMN-enhancing drugs","volume":"11","author":"Hensel","year":"2020","journal-title":"Front. Neurol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3389\/fnins.2015.00198","article-title":"Chatting with the neighbors: crosstalk between Rho-kinase (ROCK) and other signaling pathways for treatment of neurological disorders","volume":"9","author":"Hensel","year":"2015","journal-title":"Front. Neurosci."},{"key":"B92","doi-asserted-by":"publisher","first-page":"FNL25","DOI":"10.2217\/fnl-2019-0006","article-title":"Teaching an old drug new tricks: repositioning strategies for spinal muscular atrophy","volume":"14","author":"Hoolachan","year":"2019","journal-title":"Future Neurol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"e20190226","DOI":"10.1542\/peds.2019-0226","article-title":"Nusinersen for type 1 spinal muscular atrophy: a father\u2019s perspective","volume":"144","author":"Hoot","year":"2019","journal-title":"Pediatrics"},{"key":"B94","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1016\/S0960-8966(18)30330-4","article-title":"AMO-02 (tideglusib) for the treatment of congenital and childhood onset myotonic dystrophy type 1","volume":"28","author":"Horrigan","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"B95","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.ajhg.2016.07.014","article-title":"The power of human protective modifiers: PLS3 and CORO1C unravel impaired endocytosis in spinal muscular atrophy and rescue SMA phenotype","volume":"99","author":"Hosseinibarkooie","year":"2016","journal-title":"Am. J. Hum. Genet."},{"key":"B96","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s11825-016-0083-5","article-title":"Plastin 3, a human protective modifier is highly up regulated in iPSC-derived motoneurons in asymptomatic SMN1-deteted individuals and rescues spinal muscular atrophy in mice by restored endocytosis","volume":"28","author":"Hosseinibarkooie","year":"2016","journal-title":"Med. Genet."},{"key":"B97","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/nature12111","article-title":"The zebrafish reference genome sequence and its relationship to the human genome","volume":"496","author":"Howe","year":"2013","journal-title":"Nature"},{"key":"B98","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/71709","article-title":"A mouse model for spinal muscular atrophy","volume":"24","author":"Hsieh-Li","year":"2000","journal-title":"Nat. Genet."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/j.1476-5381.2010.01127.x","article-title":"Principles of early drug discovery","volume":"162","author":"Hughes","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1080\/21678421.2019.1645858","article-title":"Radicava (edaravone) for amyotrophic lateral sclerosis: US experience at 1 year after launch","volume":"20","author":"Jackson","year":"2019","journal-title":"Amyotroph. Lateral Scler. Frontotemporal Degener."},{"key":"B101","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1093\/hmg\/ddi205","article-title":"Diverse small-molecule modulators of SMN expression found by high-throughput compound screening: early leads towards a therapeutic for spinal muscular atrophy","volume":"14","author":"Jarecki","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"B102","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.1002\/14651858.CD001330","article-title":"Aminopyridines for symptomatic treatment of multiple sclerosis","volume":"173","author":"Jensen","year":"2011","journal-title":"Ugeskr. Laeger"},{"key":"B103","doi-asserted-by":"publisher","first-page":"175628642090780","DOI":"10.1177\/1756286420907803","article-title":"Experiences from treating seven adult 5q spinal muscular atrophy patients with Nusinersen","volume":"13","author":"Jochmann","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"B104","doi-asserted-by":"publisher","first-page":"e89970","DOI":"10.1172\/jci.insight.89970","article-title":"Plastin-3 extends survival and reduces severity in mouse models of spinal muscular atrophy","volume":"2","author":"Kaifer","year":"2017","journal-title":"JCI Insight"},{"key":"B105","article-title":"The pivotal Phase 3 NEPTUNE trial investigating gaboxadol in Angelman syndrome: study design (1327)","author":"Kaneko","year":"2020","journal-title":"Am. Acad. Neurol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"8326","DOI":"10.1093\/nar\/gky641","article-title":"Combined deficiency of senataxin and DNA-PKcs causes DNA damage accumulation and neurodegeneration in spinal muscular atrophy","volume":"46","author":"Kannan","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"B107","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.prrv.2018.03.003","article-title":"New and developing therapies in spinal muscular atrophy","volume":"28","author":"Kariyawasam","year":"2018","journal-title":"Paediatr. Respir. Rev."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1177\/0883073809333535","article-title":"Oral administration of the thyrotropin-releasing hormone (TRH) analogue, taltireline hydrate, in spinal muscular atrophy","volume":"24","author":"Kato","year":"2009","journal-title":"J. Child Neurol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.chembiol.2004.08.026","article-title":"A flexible data analysis tool for chemical genetic screens","volume":"11","author":"Kelley","year":"2004","journal-title":"Chem. Biol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.pediatrneurol.2017.04.013","article-title":"Effect of salbutamol on respiratory muscle strength in spinal muscular atrophy","volume":"73","author":"Khirani","year":"2017","journal-title":"Pediatr. Neurol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1002\/jcsm.12558","article-title":"Indoprofen prevents muscle wasting in aged mice through activation of PDK1\/AKT pathway","volume":"11","author":"Kim","year":"2020","journal-title":"J. Cachex., Sarco. Muscle"},{"key":"B112","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.nmd.2013.10.011","article-title":"Somatropin treatment of spinal muscular atrophy: a placebo-controlled, double-blind crossover pilot study","volume":"24","author":"Kirschner","year":"2014","journal-title":"Neuromuscul. Disord."},{"key":"B113","doi-asserted-by":"publisher","first-page":"e21296-11","DOI":"10.1371\/journal.pone.0021296","article-title":"Sma carni-val trial part II: a prospective, single-armed trial of L-carnitine and valproic acid in ambulatory children with spinal muscular atrophy","volume":"6","author":"Kissel","year":"2011","journal-title":"PLoS One"},{"key":"B114","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.nmd.2018.10.001","article-title":"The oral splicing modifier RG7800 increases full length survival of motor neuron 2 mRNA and survival of motor neuron protein: results from trials in healthy adults and patients with spinal muscular atrophy","volume":"29","author":"Kletzl","year":"2019","journal-title":"Neuromuscul. Disord."},{"key":"B115","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2018.03.008","article-title":"ROCK inhibition in models of neurodegeneration and its potential for clinical translation","volume":"189","author":"Koch","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"B116","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1096\/fj.201802554RRR","article-title":"Drosophila SMN2 minigene reporter model identifies moxifloxacin as a candidate therapy for SMA","volume":"34","author":"Konieczny","year":"2020","journal-title":"FASEB J."},{"key":"B117","first-page":"63","article-title":"Rocephin\u00ae","volume":"121","author":"Koster","year":"1986","journal-title":"Pharm. Weekbl"},{"key":"B118","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/sj.embor.7400236","article-title":"Accelerating drug discovery","volume":"5","author":"Kraljevic","year":"2004","journal-title":"EMBO Rep."},{"key":"B119","doi-asserted-by":"publisher","first-page":"3667","DOI":"10.1093\/hmg\/ddr288","article-title":"Increasing expression and decreasing degradation of SMN ameliorate the spinal muscular atrophy phenotype in mice","volume":"20","author":"Kwon","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"B120","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1016\/j.bmcl.2017.06.027","article-title":"Cyclic tetrapeptide HDAC inhibitors as potential therapeutics for spinal muscular atrophy: screening with iPSC-derived neuronal cells","volume":"27","author":"Lai","year":"2017","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"B121","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3233\/JAD-2010-1347","article-title":"Unfolded p53 in blood as a predictive signature signature of the transition from mild cognitive impairment to Alzheimer\u2019s disease","volume":"20","author":"Lanni","year":"2010","journal-title":"J. Alzheimers Dis."},{"key":"B122","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1093\/hmg\/ddi078","article-title":"SMN\u03947, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN","volume":"14","author":"Le","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"B123","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1039\/C2IB20078C","article-title":"Quantitative screening of genes regulating tryptophan hydroxylase transcription in Caenorhabditis elegans using microfluidics and an adaptive algorithm","volume":"5","author":"Lee","year":"2013","journal-title":"Integr. Biol."},{"key":"B124","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.pediatrneurol.2018.11.002","article-title":"Pre-Nusinersen hospitalization costs of children with spinal muscular atrophy","volume":"92","author":"Lee","year":"2019","journal-title":"Pediatr. Neurol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"9306","DOI":"10.1073\/pnas.151270098","article-title":"Regulation of myostatin activity and muscle growth","volume":"98","author":"Lee","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B126","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/nrg2563","article-title":"Maintaining the brain: insight into human neurodegeneration from Drosophila melanogaster mutants","volume":"10","author":"Lessing","year":"2009","journal-title":"Nat. Rev. Genet."},{"key":"B127","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1021\/cb300374h","article-title":"Small molecule screen reveals regulation of survival motor neuron protein abundance by Ras proteins","volume":"8","author":"Letso","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1002\/phar.2309","article-title":"High\u2010dose gabapentin for the treatment of severe alcohol withdrawal syndrome: a retrospective cohort analysis","volume":"39","author":"Levine","year":"2019","journal-title":"Pharmacotherapy"},{"key":"B129","doi-asserted-by":"publisher","first-page":"115425","DOI":"10.1016\/j.bmc.2020.115425","article-title":"High throughput in vivo phenotypic screening for drug repurposing: discovery of MLR-1023 a novel insulin sensitizer and novel Lyn kinase activator with clinical proof of concept","volume":"28","author":"Lipinski","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"B130","first-page":"9","article-title":"Outcome of specific COX-2 inhibition in rheumatoid arthritis","volume":"49","author":"Lipsky","year":"1997","journal-title":"J. Rheumatol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1741-7015-11-38","article-title":"Sodium vanadate combined with l-ascorbic acid delays disease progression, enhances motor performance, and ameliorates muscle atrophy and weakness in mice with spinal muscular atrophy","volume":"11","author":"Liu","year":"2013","journal-title":"BMC Med."},{"key":"B132","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1093\/hmg\/ddy382","article-title":"Specific inhibition of myostatin activation is beneficial in mouse models of SMA therapy","volume":"28","author":"Long","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"B133","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1038\/s41598-019-39738-6","article-title":"Growth hormone improves nerve regeneration, muscle re-innervation, and functional outcomes after chronic denervation injury","volume":"9","author":"Lopez","year":"2019","journal-title":"Sci. Rep."},{"key":"B134","doi-asserted-by":"publisher","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","article-title":"A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy","volume":"96","author":"Lorson","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B135","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1093\/bib\/bbx017","article-title":"A review of network-based approaches to drug repositioning","volume":"19","author":"Lotfi Shahreza","year":"2018","journal-title":"Briefings Bioinf."},{"key":"B136","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3233\/JAD-141959","article-title":"A phase II trial of tideglusib in Alzheimer\u2019s disease","volume":"45","author":"Lovestone","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"B137","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1586\/era.11.175","article-title":"Hydroxyurea: a key player in cancer chemotherapy","volume":"12","author":"Madaan","year":"2012","journal-title":"Expet Rev. Anticancer Ther."},{"key":"B138","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1002\/(SICI)1097-4598(199809)21:9<1196::AID-MUS11>3.0.CO;2-Q","article-title":"Effect of 3,4-diaminopyridine on the time course of decay of compound muscle action potential augmentation in the Lambert-Eaton myasthenic syndrome","volume":"21","author":"Maddison","year":"1998","journal-title":"Muscle Nerve"},{"key":"B139","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nchembio.595","article-title":"A screen for regulators of survival of motor neuron protein levels","volume":"7","author":"Makhortova","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"B140","doi-asserted-by":"publisher","first-page":"664","DOI":"10.2174\/1570159x15666170823095628","article-title":"In silico studies in drug research against neurodegenerative diseases","volume":"16","author":"Makhouri","year":"2017","journal-title":"Curr. Neuropharmacol."},{"key":"B141","doi-asserted-by":"publisher","first-page":"1601484","DOI":"10.1080\/20016689.2019.1601484","article-title":"Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients","volume":"7","author":"Malone","year":"2019","journal-title":"J. Mark. Access Health Policy"},{"key":"B142","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1038\/s41467-017-01486-4","article-title":"Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches","volume":"8","author":"Mariot","year":"2017","journal-title":"Nat. Commun."},{"key":"B143","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2174\/1389202919666180101154916","article-title":"Molecular factors involved in spinal muscular atrophy pathways as possible disease-modifying candidates","volume":"19","author":"Maru","year":"2018","journal-title":"Curr. Genomics"},{"key":"B144","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/sj.npp.1300641","article-title":"Effect of repeated gaboxadol administration on night sleep and next-day performance in healthy elderly subjects","volume":"30","author":"Mathias","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"B145","doi-asserted-by":"publisher","first-page":"CD003725","DOI":"10.1002\/14651858.CD003725.pub4","article-title":"Corticosteroids for the treatment of duchenne muscular dystrophy","volume":"5","author":"Matthews","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"B146","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S1474-4422(20)30068-5","article-title":"Nusinersen in adults with spinal muscular atrophy: new challenges","volume":"19","author":"Mercuri","year":"2020","journal-title":"Lancet Neurol."},{"key":"B147","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.neuron.2010.12.032","article-title":"Early functional impairment of sensory-motor connectivity in a mouse model of spinal muscular atrophy","volume":"69","author":"Mentis","year":"2011","journal-title":"Neuron"},{"key":"B148","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.neurol.2009.07.016","article-title":"Eurosmart: european spinal muscular atrophy randomised trial of acetyl-L-carnitine in spinal muscular atrophy","volume":"166","author":"Merlini","year":"2010","journal-title":"Rev. Neurol. (Paris)"},{"key":"B149","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/s0960-8966(01)00272-3","article-title":"90th ENMC international workshop: European spinal muscular atrophy randomised trial (EuroSMART) 9-10 February 2001, Naarden, The Netherlands","volume":"12","author":"Merlini","year":"2002","journal-title":"Neuromuscul. Disord."},{"key":"B150","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1177\/08830738030180080501","article-title":"Role of gabapentin in spinal muscular atrophy","volume":"18","author":"Merlini","year":"2003","journal-title":"J. Child Neurol."},{"key":"B151","doi-asserted-by":"publisher","first-page":"S96","DOI":"10.1016\/S1090-3798(11)70332-4","article-title":"Response to daily salbutamol in spinal muscular atrophy type III","volume":"15","author":"McCullagh","year":"2011","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"B152","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1534\/genetics.115.179457","article-title":"Drosophilaas anIn VivoModel for human neurodegenerative disease","volume":"201","author":"McGurk","year":"2015","journal-title":"Genetics"},{"key":"B153","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.cbpa.2007.08.033","article-title":"Virtual screening strategies in drug discovery","volume":"11","author":"McInnes","year":"2007","journal-title":"Curr. Opin. Chem. Biol."},{"key":"B154","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0022-510X(01)00632-3","article-title":"A placebo-controlled trial of gabapentin in spinal muscular atrophy","volume":"191","author":"Miller","year":"2001","journal-title":"J. Neurol. Sci."},{"key":"B155","doi-asserted-by":"publisher","first-page":"6493","DOI":"10.1523\/JNEUROSCI.0206-11.2011","article-title":"The canonical nuclear factor- B pathway regulates cell survival in a developmental model of spinal cord motoneurons","volume":"31","author":"Mincheva","year":"2011","journal-title":"J. Neurosci."},{"key":"B156","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-642-75720-4_1","article-title":"Aclarubicin in single agent and combined chemotherapy of adult acute myeloid leukemia","volume-title":"New findings on aclarubicin in the treatment of acute myeloid leukemia","author":"Mitrou","year":"1990"},{"key":"B157","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.trci.2017.10.005","article-title":"Drug discovery and development: role of basic biological research","volume":"3","author":"Mohs","year":"2017","journal-title":"Alzheimer's Dement."},{"key":"B158","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1093\/hmg\/8.7.1177","article-title":"A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2","volume":"8","author":"Monani","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"B159","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1093\/hmg\/9.3.333","article-title":"The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn-\/- mice and results in a mouse with spinal muscular atrophy","volume":"9","author":"Monani","year":"2000","journal-title":"Hum. Mol. Genet."},{"key":"B160","first-page":"CD007938","article-title":"Gabapentin for chronic neuropathic pain and fibromyalgia in adults","volume-title":"Cochrane database of systematic reviews","author":"Moore","year":"2011"},{"key":"B161","first-page":"1023","article-title":"Transcriptional and posttranscriptional regulation of erythroid gene expression in anthracycline-induced differentiation of human erythroleukemic cells","volume":"7","author":"Morceau","year":"1996","journal-title":"Cell Growth Differ. Mol. Biol. J. Am. Assoc. Cancer Res."},{"key":"B162","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/nature01262","article-title":"Initial sequencing and comparative analysis of the mouse genome","volume":"420","author":"Waterston","year":"2002","journal-title":"Nature"},{"key":"B163","doi-asserted-by":"publisher","first-page":"e96","DOI":"10.1097\/MJT.0000000000000535","article-title":"Lamotrigine uses in psychiatric practice","volume":"26","author":"Naguy","year":"2019","journal-title":"Am. J. Therapeut."},{"key":"B164","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1126\/science.1250127","article-title":"SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy","volume":"345","author":"Naryshkin","year":"2014","journal-title":"Science"},{"key":"B165","doi-asserted-by":"publisher","first-page":"127","DOI":"10.33588\/rn.5002.2009267","article-title":"Lamotrigina en los s\u00edntomas motores de las atrofias musculares espinales","volume":"50","author":"Nascimento","year":"2010","journal-title":"RevNeurol"},{"key":"B166","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1017\/s1461145707008401","article-title":"Oxidative stress in psychiatric disorders: evidence base and therapeutic implications","volume":"11","author":"Ng","year":"2008","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"B167","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.expneurol.2011.01.017","article-title":"Beta-lactam antibiotic offers neuroprotection in a spinal muscular atrophy model by multiple mechanisms","volume":"229","author":"Nizzardo","year":"2011","journal-title":"Exp. Neurol."},{"key":"B168","doi-asserted-by":"publisher","first-page":"4865","DOI":"10.1093\/hmg\/ddr425","article-title":"The spinal muscular atrophy disease protein SMN is linked to the rho-kinase pathway via profilin","volume":"20","author":"N\u00f6lle","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"B169","volume-title":"Media release media release media release Zolgensma \u00ae data shows rapid, significant, clinically meaningful benefit in SMA including prolonged event- free survival, motor milestone achievement and durability now up to 5 years post-dosing","year":"2020"},{"key":"B170","doi-asserted-by":"publisher","first-page":"152","DOI":"10.5966\/sctm.2015-0059","article-title":"Established stem cell model of spinal muscular atrophy is applicable in the evaluation of the efficacy of thyrotropin-releasing hormone analog","volume":"5","author":"Ohuchi","year":"2016","journal-title":"Stem Cells Transl. Med."},{"key":"B171","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1126\/science.1155085","article-title":"Plastin 3 is a protective modifier of autosomal recessive spinal muscular atrophy","volume":"320","author":"Oprea","year":"2008","journal-title":"Science"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.31525\/cmr-1e36741","article-title":"Bassell: reldesemtiv, treatment of spinal muscular atrophy","year":"2019","journal-title":"Case Med. Res."},{"key":"B173","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41596-019-0248-1","article-title":"On-chip 3D neuromuscular model for drug screening and precision medicine in neuromuscular disease","volume":"15","author":"Osaki","year":"2020","journal-title":"Nat. Protoc."},{"key":"B174","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.1093\/hmg\/dds285","article-title":"Characterization of behavioral and neuromuscular junction phenotypes in a novel allelic series of SMA mouse models","volume":"21","author":"Osborne","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"B175","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-45822-8","article-title":"Functional characterization of SMN evolution in mouse models of SMA","volume":"9","author":"Osman","year":"2019","journal-title":"Sci. Rep."},{"key":"B176","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/0306-3623(89)90206-1","article-title":"Evidence of a central component in the analgesic effect of indoprofene","volume":"20","author":"Paeile","year":"1989","journal-title":"Gen. Pharmacol. Vasc. Syst."},{"key":"B177","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/jnc.14935","article-title":"Combined treatment with the histone deacetylase inhibitor LBH589 and a splice\u2010switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in spinal muscular atrophy cells","volume":"153","author":"Pagliarini","year":"2020","journal-title":"J. Neurochem."},{"key":"B178","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/nchembio.1837","article-title":"SMN2 splice modulators enhance U1-pre-mRNA association and rescue SMA mice","volume":"11","author":"Palacino","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"B179","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.nmd.2008.05.004","article-title":"Daily salbutamol in young patients with SMA type II","volume":"18","author":"Pane","year":"2008","journal-title":"Neuromuscul. Disord."},{"key":"B180","doi-asserted-by":"publisher","first-page":"3928","DOI":"10.3390\/ijms21113928","article-title":"Mitochondria: a galaxy in the hematopoietic and leukemic stem cell universe","volume":"21","author":"Panuzzo","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B181","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1242\/dmm.015719","article-title":"Fishing for causes and cures of motor neuron disorders","volume":"7","author":"Patten","year":"2014","journal-title":"Dis. Models Mech."},{"key":"B182","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.sedene.2015.05.002","article-title":"Uso de fampyra para la mejor\u00eda de la marcha en el paciente con esclerosis m\u00faltiple y sus repercusiones en la calidad de vida del paciente","volume":"42","author":"P\u00e9rez Luque","year":"2015","journal-title":"Rev. Cient\u00ed. Soc. Esp. Enfer. Neurol\u00f3"},{"key":"B183","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.expneurol.2016.06.032","article-title":"Autophagy modulators regulate survival motor neuron protein stability in motoneurons","volume":"283","author":"Periyakaruppiah","year":"2016","journal-title":"Exp. Neurol."},{"key":"B184","article-title":"Neurontin\u00ae (gabapentin) capsules Neurontin\u00ae (gabapentin) tablets neurontin \u00ae (gabapentin) oral solution","year":"2009"},{"key":"B185","unstructured":"2015"},{"key":"B186","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1038\/s41419-017-0086-4","article-title":"Inhibition of autophagy delays motoneuron degeneration and extends lifespan in a mouse model of spinal muscular atrophy","volume":"8","author":"Piras","year":"2017","journal-title":"Cell Death Dis."},{"key":"B187","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/jnc.14974","article-title":"Combinatorial treatment for spinal muscular atrophy","volume":"153","author":"Poletti","year":"2020","journal-title":"J. Neurochem."},{"key":"B188","doi-asserted-by":"publisher","first-page":"e00447-12","DOI":"10.1002\/prp2.447","article-title":"Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs","volume":"6","author":"Poirier","year":"2018","journal-title":"Pharmacol. Res. Perspect."},{"key":"B189","doi-asserted-by":"publisher","first-page":"e87908","DOI":"10.1172\/jci.insight.87908","article-title":"Systemic restoration of UBA1 ameliorates disease in spinal muscular atrophy","volume":"1","author":"Powis","year":"2016","journal-title":"JCI Insight"},{"key":"B190","unstructured":"2013"},{"key":"B191","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.4155\/fmc.10.228","article-title":"Drug discovery and development for spinal muscular atrophy: lessons from screening approaches and future challenges for clinical development","volume":"2","author":"Pruss","year":"2010","journal-title":"Future Med. Chem."},{"key":"B192","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"B193","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1038\/s41598-018-20524-9","article-title":"Blocking extracellular activation of myostatin as a strategy for treating muscle wasting","volume":"8","author":"Puyal","year":"2018","journal-title":"Sci. Rep."},{"key":"B194","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1172\/JCI91445","article-title":"Intermittent glucocorticoid steroid dosing enhances muscle repair without eliciting muscle atrophy","volume":"127","author":"Quattrocelli","year":"2017","journal-title":"J. Clin. Invest."},{"key":"B195","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1083\/jcb.200610053","article-title":"A Drosophila melanogaster model of spinal muscular atrophy reveals a function for SMN in striated muscle","volume":"176","author":"Rajendra","year":"2007","journal-title":"J. Cell Biol."},{"key":"B196","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.pneurobio.2018.06.011","article-title":"Insights into the pharmaceuticals and mechanisms of neurological orphan diseases: current status and future expectations","volume":"169","author":"Ramalho","year":"2018","journal-title":"Prog. Neurobiol."},{"key":"B197","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1080\/14656566.2019.1704732","article-title":"New treatments in spinal muscular atrophy: an overview of currently available data","volume":"21","author":"Ramdas","year":"2020","journal-title":"Expet Opin. Pharmacother."},{"key":"B198","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.18553\/jmcp.2018.24.12-a.s3","article-title":"Gene therapy for spinal muscular atrophy: an emerging treatment option for a devastating disease","volume":"24","author":"Rao","year":"2018","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"B199","doi-asserted-by":"publisher","first-page":"6501","DOI":"10.1021\/acs.jmedchem.8b00741","article-title":"Discovery of risdiplam, a selective survival of motor neuron-2 (SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA)","volume":"61","author":"Ratni","year":"2018","journal-title":"J. Med. Chem."},{"key":"B200","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1051\/medsci\/2019049","article-title":"Nusinersen chez l\u2019enfant : \u00e9volution ou r\u00e9volution ?","volume":"35","author":"Richelme","year":"2019","journal-title":"Med. Sci."},{"key":"B201","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.ajhg.2017.01.005","article-title":"Neurocalcin delta suppression protects against spinal muscular atrophy in humans and across species by restoring impaired endocytosis","volume":"100","author":"Riessland","year":"2017","journal-title":"Am. J. Hum. Genet."},{"key":"B202","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-44222-2","article-title":"Nerve sprouting capacity in a pharmacologically induced mouse model of spinal muscular atrophy","volume":"9","author":"Rimer","year":"2019","journal-title":"Sci. Rep."},{"key":"B203","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1056\/NEJM199004123221504","article-title":"Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea","volume":"322","author":"Rodgers","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"B204","first-page":"A4272","article-title":"A randomized, double-blind, placebo-controlled, crossover study to assess the effect of reldesemtiv on exercise tolerance in subjects with chronic obstructive pulmonary disease","author":"Rossiter","year":"2019"},{"key":"B205","doi-asserted-by":"publisher","first-page":"30","DOI":"10.5664\/jcsm.27707","article-title":"Effect of gaboxadol on patient-reported measures of sleep and waking function in patients with primary insomnia: results from two randomized, controlled, 3-month studies","volume":"6","author":"Roth","year":"2010","journal-title":"J. Clin. Sleep Med"},{"key":"B206","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/ana.410380114","article-title":"Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis","volume":"38","author":"Rothstein","year":"1995","journal-title":"Ann. Neurol."},{"key":"B207","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1007\/s00018-019-03386-w","article-title":"Molecular mechanism of olesoxime-mediated neuroprotection through targeting \u03b1-synuclein interaction with mitochondrial VDAC","volume":"77","author":"Rovini","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"key":"B208","article-title":"CY 5021 A phase 2, double-blind, randomized, placebo-controlled, multiple-dose study of reldesemtiv 2 ascending-dose cohorts of patients with spinal muscular atrophy (SMA)","author":"Rudnicki","year":"2018"},{"key":"B209","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1001\/archneur.60.11.1601","article-title":"A phase 1 trial of riluzole in spinal muscular atrophy","volume":"60","author":"Russman","year":"2003","journal-title":"Arch. Neurol."},{"key":"B210","doi-asserted-by":"publisher","first-page":"e43990","DOI":"10.1371\/journal.pone.0043990","article-title":"Liuwei dihuang (LWDH), a traditional Chinese medicinal formula, protects against \u03b2-Amyloid toxicity in transgenic Caenorhabditis elegans","volume":"7","author":"Sangha","year":"2012","journal-title":"PLoS One"},{"key":"B211","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.biomaterials.2018.02.047","article-title":"Stem cell derived phenotypic human neuromuscular junction model for dose response evaluation of therapeutics","volume":"166","author":"Santhanam","year":"2018","journal-title":"Biomaterials"},{"key":"B212","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1093\/bib\/bbx125","article-title":"Web-based drug repurposing tools: a survey","volume":"20","author":"Sam","year":"2019","journal-title":"Briefings Bioinf."},{"key":"B272","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3389\/fnmol.2018.00308","article-title":"Pharmacological c-Jun NH2-Terminal Kinase (JNK) Pathway Inhibition Reduces Severity of Spinal Muscular Atrophy Disease in Mice","volume":"11","author":"Schellino","year":"2018","journal-title":"Front. Mol. Neurosci."},{"key":"B213","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1179\/joc.2005.17.Supplement-2.33","article-title":"Predicting the clinical efficacy of generic formulations of ceftriaxone","volume":"17","author":"Schito","year":"2005","journal-title":"J. Chemother."},{"key":"B214","unstructured":"Financial results and highlights business progress2020"},{"key":"B215","doi-asserted-by":"publisher","first-page":"12013","DOI":"10.1073\/pnas.91.25.12013","article-title":"Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain","volume":"91","author":"Seibert","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B216","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1016\/j.bbadis.2013.08.005","article-title":"Spinal muscular atrophy: an update on therapeutic progress","volume":"1832","author":"Seo","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"B217","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1089\/hum.2010.114","article-title":"Combination of SMN trans-splicing and a neurotrophic factor increases the life span and body mass in a severe model of spinal muscular atrophy","volume":"22","author":"Shababi","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"B218","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1080\/21678421.2018.1510576","article-title":"Theme 9 clinical trials and trial design","volume":"19","author":"Shefner","year":"2018","journal-title":"Amyotroph. Lateral Scler. Front. Degener."},{"key":"B219","first-page":"819","article-title":"Treatment of cerebral vasospasm by a protein kinase inhibitor AT 877","volume":"45","author":"Shibuya","year":"1993","journal-title":"No To Shinkei"},{"key":"B220","first-page":"100","article-title":"Effects of a new TRH analogue, YM-14673, on spontaneous motor activity in rats","volume":"301","author":"Shimizu","year":"1989","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"key":"B221","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s40265-018-0868-8","article-title":"Overview of current drugs and molecules in development for spinal muscular atrophy therapy","volume":"78","author":"Shorrock","year":"2018","journal-title":"Drugs"},{"key":"B222","doi-asserted-by":"publisher","first-page":"bbaa034","DOI":"10.1093\/bib\/bbaa034","article-title":"Virtual screening web servers: designing chemical probes and drug candidates in the cyberspace","author":"Singh","year":"2020","journal-title":"Briefings Bioinf."},{"key":"B223","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1021\/cb800120t","article-title":"DcpS as a therapeutic target for spinal muscular atrophy","volume":"3","author":"Singh","year":"2008","journal-title":"ACS Chem. Biol."},{"key":"B224","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1128\/mcb.26.4.1333-1346.2006","article-title":"Splicing of a critical exon of human survival motor neuron is regulated by a unique silencer element located in the last intron","volume":"26","author":"Singh","year":"2006","journal-title":"Mol. Cell. Biol."},{"key":"B225","doi-asserted-by":"publisher","first-page":"3767","DOI":"10.1016\/j.celrep.2017.12.003","article-title":"Converging mechanisms of p53 activation drive motor neuron degeneration in spinal muscular atrophy","volume":"21","author":"Simon","year":"2017","journal-title":"Cell Rep."},{"key":"B226","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/hmg\/ddq459","article-title":"A novel Caenorhabditis elegans allele, smn-1(cb131), mimicking a mild form of spinal muscular atrophy, provides a convenient drug screening platform highlighting new and pre-approved compounds","volume":"20","author":"Sleigh","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"B227","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1093\/jnen\/62.4.420","article-title":"Downregulation of Bcl-2 proteins in type I spinal muscular atrophy motor neurons during fetal development","volume":"62","author":"Soler-Botija","year":"2003","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"B228","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1089\/scd.2018.0181","article-title":"A SMN2 splicing modifier rescues the disease phenotypes in an in vitro human spinal muscular atrophy model","volume":"28","author":"Son","year":"2019","journal-title":"Stem Cell. Dev."},{"key":"B229","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3389\/fneur.2018.00384","article-title":"A role for GDNF and soluble APP as biomarkers of amyotrophic lateral sclerosis pathophysiology","volume":"9","author":"Stanga","year":"","journal-title":"Front. Neurol."},{"key":"B230","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.3390\/ijms21103719","article-title":"Mitochondrial dysfunctions: a red thread across neurodegenerative diseases","volume":"21","author":"Stanga","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B231","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.2174\/156720512804142886","article-title":"Searching for predictive blood biomarkers: misfolded p53 in mild cognitive impairment","volume":"9","author":"Stanga","year":"2012","journal-title":"Curr. Alzheimer Res."},{"key":"B232","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1111\/jcmm.13364","article-title":"Specificity of presenilin-1- and presenilin-2-dependent \u03b3-secretases towards substrate processing","volume":"22","author":"Stanga","year":"","journal-title":"J. Cell Mol. Med."},{"key":"B233","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1096\/fj.15-278739","article-title":"APP\u2010dependent glial cell line\u2010derived neurotrophic factor gene expression drives neuromuscular junction formation","volume":"30","author":"Stanga","year":"2016","journal-title":"FASEB J."},{"key":"B234","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1002\/mds.26580","article-title":"Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy","volume":"31","author":"Stamelou","year":"2016","journal-title":"Mov. Disord."},{"key":"B235","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1177\/1060028020914274","article-title":"Onasemnogene abeparvovec-xioi: gene therapy for spinal muscular atrophy","volume":"54","author":"Stevens","year":"2020","journal-title":"Ann. Pharmacother."},{"key":"B236","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3389\/fncel.2019.00015","article-title":"The alteration of intrinsic excitability and synaptic transmission in lumbar spinal motor neurons and interneurons of severe spinal muscular atrophy mice","volume":"13","author":"Sun","year":"2019","journal-title":"Front. Cell. Neurosci."},{"key":"B237","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.4103\/njcp.njcp_367_18","article-title":"Clinical observation in edaravone treatment for acute cerebral infarction","volume":"22","author":"Sun","year":"2019","journal-title":"Niger. J. Clin. Pract."},{"key":"B238","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1002\/ana.10743","article-title":"Valproic acid increases SMN levels in spinal muscular atrophy patient cells","volume":"54","author":"Sumner","year":"2003","journal-title":"Ann. Neurol."},{"key":"B239","doi-asserted-by":"publisher","first-page":"115239","DOI":"10.1016\/j.bmc.2019.115239","article-title":"Expanding therapeutic opportunities for neurodegenerative diseases: A perspective on the important role of phenotypic screening","volume":"28","author":"Swalley","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"B240","doi-asserted-by":"publisher","first-page":"e12140","DOI":"10.1371\/journal.pone.0012140","article-title":"SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy","volume":"5","author":"Swoboda","year":"2010","journal-title":"PLoS One"},{"key":"B241","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1177\/088307389400900313","article-title":"Efficacy of thyrotropin-releasing hormone in the treatment of spinal muscular atrophy","volume":"9","author":"Takeuchi","year":"1994","journal-title":"J. Child Neurol."},{"key":"B242","doi-asserted-by":"publisher","first-page":"100826","DOI":"10.1016\/j.isci.2020.100826","article-title":"R-roscovitine improves motoneuron function in mouse models for spinal muscular atrophy","volume":"23","author":"Tejero","year":"2020","journal-title":"iScience"},{"key":"B243","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1136\/jmg.2010.080366","article-title":"Salbutamol increases survival motor neuron (SMN) transcript levels in leucocytes of spinal muscular atrophy (SMA) patients: relevance for clinical trial design","volume":"47","author":"Tiziano","year":"2010","journal-title":"J. Med. Genet."},{"key":"B244","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/bs.pmbts.2015.10.008","article-title":"Effects of growth hormone on bone","volume":"138","author":"Tritos","year":"2016","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"B245","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/456478","article-title":"Therapy development for spinal muscular atrophy in SMN independent targets","volume":"2012","author":"Tsai","year":"2012","journal-title":"Neural Plast."},{"key":"B246","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1038\/mt.2014.84","article-title":"Systemic administration of a recombinant AAV1 vector encoding IGF-1 improves disease manifestations in SMA mice","volume":"22","author":"Tsai","year":"2014","journal-title":"Mol. Ther."},{"key":"B247","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.nbd.2008.05.014","article-title":"Restoring Bcl-xL levels benefits a mouse model of spinal muscular atrophy","volume":"31","author":"Tsai","year":"2008","journal-title":"Neurobiol. Dis."},{"key":"B248","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.ymthe.2006.02.008","article-title":"Abolishing bax-dependent apoptosis shows beneficial effects on spinal muscular atrophy model mice","volume":"13","author":"Tsai","year":"2006","journal-title":"Mol. Ther."},{"key":"B249","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.phymed.2013.11.001","article-title":"The Chinese herbal formula Liuwei dihuang protects dopaminergic neurons against Parkinson's toxin through enhancing antioxidative defense and preventing apoptotic death","volume":"21","author":"Tseng","year":"2014","journal-title":"Phytomedicine"},{"key":"B250","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.phymed.2017.08.018","article-title":"The water extract of Liuwei dihuang possesses multi-protective properties on neurons and muscle tissue against deficiency of survival motor neuron protein","volume":"34","author":"Tseng","year":"2017","journal-title":"Phytomedicine"},{"key":"B251","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1080\/14728222.2016.1188079","article-title":"Therapeutic augmentation of the growth hormone axis to improve outcomes following peripheral nerve injury","volume":"20","author":"Tuffaha","year":"2016","journal-title":"Expert Opin. Ther. Targets"},{"key":"B252","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1097\/00002060-200009000-00005","article-title":"A study of thyrotropin-releasing hormone for the treatment of spinal muscular atrophy","volume":"79","author":"Tzeng","year":"2000","journal-title":"Am. J. Phys. Med. Rehabil."},{"key":"B253","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/S0024-3205(02)02268-3","article-title":"Neuroprotective effect and brain receptor binding of taltirelin, a novel thyrotropin-releasing hormone (TRH) analogue, in transient forebrain ischemia of C57BL\/6J mice","volume":"72","author":"Urayama","year":"2002","journal-title":"Life Sci."},{"key":"B254","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1007\/s11136-018-1945-x","article-title":"Measuring quality of life in children with spinal muscular atrophy: a systematic literature review","volume":"27","author":"Vaidya","year":"2018","journal-title":"Qual. Life Res."},{"key":"B255","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.ymthe.2020.01.013","article-title":"miR-206 reduces the severity of motor neuron degeneration in the facial nuclei of the brainstem in a mouse model of SMA","volume":"28","author":"Valsecchi","year":"2020","journal-title":"Mol. Ther."},{"key":"B256","doi-asserted-by":"publisher","first-page":"e0128560-17","DOI":"10.1371\/journal.pone.0128560","article-title":"Expression of muscle-specific MiRNA 206 in the progression of disease in a murine SMA model","volume":"10","author":"Valsecchi","year":"2015","journal-title":"PLoS One"},{"key":"B257","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1007\/s00415-017-8549-1","article-title":"A multi-source approach to determine SMA incidence and research ready population","volume":"264","author":"Verhaart","year":"2017","journal-title":"J. Neurol."},{"key":"B258","doi-asserted-by":"publisher","first-page":"CD006282","DOI":"10.1002\/14651858.CD006282.pub5","article-title":"Drug treatment for spinal muscular atrophy types II and III","volume":"1","author":"Wadman","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"B259","doi-asserted-by":"publisher","first-page":"e201800268-19","DOI":"10.26508\/lsa.201800268","article-title":"Drug screening with human SMN2 reporter identifies SMN protein stabilizers to correct SMA pathology","volume":"2","author":"Wang","year":"2019","journal-title":"Life Sci. Alliance"},{"key":"B260","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ebiom.2018.04.024","article-title":"Interventions targeting glucocorticoid-kr\u00fcppel-like factor 15-branched-chain amino acid signaling improve disease phenotypes in spinal muscular atrophy mice","volume":"31","author":"Walter","year":"2018","journal-title":"EBioMedicine"},{"key":"B261","doi-asserted-by":"publisher","first-page":"3399","DOI":"10.1093\/hmg\/ddn234","article-title":"SMN complex localizes to the sarcomeric Z-disc and is a proteolytic target of calpain","volume":"17","author":"Walker","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"B262","doi-asserted-by":"publisher","first-page":"CD007938","DOI":"10.1002\/14651858.CD007938.pub4","article-title":"Gabapentin for chronic neuropathic pain in adults","volume":"6","author":"Wiffen","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"B263","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1172\/JCI71318","article-title":"Dysregulation of ubiquitin homeostasis and \u03b2-catenin signaling promote spinal muscular atrophy","volume":"124","author":"Wishart","year":"2014","journal-title":"J. Clin. Invest."},{"key":"B264","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/B978-0-12-384878-9.00015-7","article-title":"Watching worms whither","volume":"100","author":"Wolozin","year":"2011","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"B265","doi-asserted-by":"publisher","first-page":"ENEURO.0289-18.2018","DOI":"10.1523\/ENEURO.0289-18.2018","article-title":"Enhancing GABAergic transmission improves locomotion in a caenorhabditis elegans model of spinal muscular atrophy","volume":"5","author":"Wu","year":"2018","journal-title":"eNeuro"},{"key":"B266","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1038\/sj.gt.3301550","article-title":"An in vivo reporter system for measuring increased inclusion of exon 7 in SMN2 mRNA: potential therapy of SMA","volume":"8","author":"Zhang","year":"2001","journal-title":"Gene Ther."},{"key":"B267","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2176\/nmc.46.421","article-title":"Effect of fasudil hydrochloride, a protein kinase inhibitor, on cerebral vasospasm and delayed cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage","volume":"46","author":"Zhao","year":"2006","journal-title":"Neurol. Med.-Chir."},{"key":"B268","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1523\/JNEUROSCI.3534-15.2016","article-title":"Defects in motoneuron-astrocyte interactions in spinal muscular atrophy","volume":"36","author":"Zhou","year":"2016","journal-title":"J. Neurosci."},{"key":"B269","unstructured":""},{"key":"B270","unstructured":""},{"key":"B271","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s40273-019-00769-6","article-title":"Cost effectiveness of Nusinersen in the treatment of patients with infantile-onset and later-onset spinal muscular atrophy in Sweden","volume":"37","author":"Zuluaga-Sanchez","year":"2019","journal-title":"Pharmacoeconomics"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2020.592234\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T05:48:29Z","timestamp":1605160109000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2020.592234\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,12]]},"references-count":272,"alternative-id":["10.3389\/fphar.2020.592234"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2020.592234","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,12]]},"article-number":"592234"}}